- Home
- CTO vs RIGL Comparison
CTO vs RIGL Comparison
Compare CTO & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | RIGL |
|---|---|---|
| Founded | 1902 | 1996 |
| Country | United States | United States |
| Employees | 42 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.9M | 564.7M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | CTO | RIGL |
|---|---|---|
| Price | $21.47 | $38.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $22.50 | ★ $45.67 |
| AVG Volume (30 Days) | 309.3K | ★ 325.8K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 7.44% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $7.63 | N/A |
| Revenue Next Year | $2.76 | $12.75 |
| P/E Ratio | ★ N/A | $84.07 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $15.07 | $18.24 |
| 52 Week High | $21.45 | $52.24 |
Technical Indicators
Market Signals| Indicator | CTO | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 64.11 | 78.67 |
| Support Level | $19.76 | $33.39 |
| Resistance Level | N/A | $44.85 |
| Average True Range (ATR) | 0.37 | 1.51 |
| MACD | 0.05 | 0.63 |
| Stochastic Oscillator | 97.18 | 93.97 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.